Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Investor Presentation (August 2023)
29 slides from Trendlines's investor presentation, August 2023
Slide 1: Investing to improve the human condition
Investing to improve the human condition Food and Health Steve Rhodes Todd Dollinger Haim Brosh Chair and CEO Chair and CEO CFO August 2023
Slide 2: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Who we are
Who we are Trendlines is an Israel-based company that trades in Singapore on the SGX (42T) and in the USA on the OTCQX (TRNLY). 3
Slide 4: We invest in agrifood and medical tech innovation to improve the human condition
We invest in agrifood and medical tech innovation to improve the human condition 16 years’ investment 54* portfolio 20 advanced-stage 10 exits and company companies companies building experience * including consolidated portfolio companies 9.7X return and 175% IRR on exits Equity US$104 million (30.
Slide 5: Leadership
Leadership Todd Dollinger Steve Rhodes Haim Brosh Chair and CEO Chair and CEO CFO Trendlines’ Founder; Trendlines’ Founder; 20 years’ over 40 years’ over 40 years’ managerial experience experience, deep and financial developing innovative understanding of experience in products from investing and bu
Slide 6: Board of Directors
Board of Directors Todd Dollinger Steve Rhodes Elka Nir Zeev Bronfeld Chair and CEO Chair and CEO Lead Independent Non-Executive Director Director Trendlines’ Founder; Trendlines’ Founder; Significant experience over 40 years’ over 40 years’ 30 years’ experience in the management experience experien
Slide 7: Strategic partnerships for growth
Strategic partnerships for growth Chairman Vincent Tchenguiz • Librae Holdings is Trendlines’ • Investor in Trendlines’ IPO, • Co-founded venture fund with largest shareholder (28%) holding 2.8% Trendlines for innovative agrifood investing • Trendfood has invested $10M in • Investor and acquirer of
Slide 8: A taste of our portfolio
A taste of our portfolio. “s: trendlines
Slide 9: Some portfolio stats
Some portfolio stats 54* 17 20 8 portfolio revenue-stage companies with consolidated companies companies strategic companies partnerships 20 34 agrifood medtech * including consolidated portfolio companies 9
Slide 10: The natural food color revolution
The natural food color revolution A broad-spectrum of healthy plant-based colors produced via Founded 2018; fermentation technology, using baker’s yeast as a biofactory. 23 employees; Phytolon’s high-quality and cost-effective pigments offer value Yokne’am Illit, IL for consumers, the environment an
Slide 11: 4 more agrifood frontrunners
4 more agrifood frontrunners 20 agrifood portfolio companies Biological, Technology platform for Artificial intelligence Orally-administered disease environmentally-friendly harvesting greenhouse analytics employing drones prevention for shrimp and technology to control tomatoes for user-generated d
Slide 12: Nonsurgical prolapse repair device
Nonsurgical prolapse repair device Minimally invasive, nonsurgical, incision-free and mesh-free repair device to treat pelvic organ prolapse (POP) in the ambulatory or office-based settings. Founded 2014 Achievements CEO • Received FDA clearance Edit Goldberg • Successful completion of 1-year follow
Slide 13: 4 more leading medtech companies
4 more leading medtech companies 34 medtech portfolio companies Meniscus repair system Cryotherapy for treatment Next-generation aspiration A small, game-changing • FDA and CE clearance of superficial bladder cancer catheter for treating ischemic device to prevent preterm birth. stroke. • Launched i
Slide 14: Let's look at the numbers
Let’s look at the numbers. “s: trendlines
Slide 15: IFRS portfolio value
IFRS portfolio value US$ millions 160 140 Portfolio value (w/o 8 consolidated companies) 120 Cumulative exit proceeds 100 80 60 40 20 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 H1 2023 15
Slide 16: Portfolio cluster values
Portfolio cluster values Non-IFRS Value Fair Value of Trendlines’ Share To better evaluate our portfolio, we divided Cluster of Trendlines’ (additional Share (US$'000) information) it into 12 “clusters”, based on their activities. (US$'000) Aquaculture & Animal Health US$5,488 US$8,796 Here is the t
Slide 17: Non-IFRS portfolio cluster values changes
Non-IFRS portfolio cluster values changes Portfolio cluster values FY 2022 vs H1 2023 30000 FY 2022 Non-IFRS Value 25000 H1 2023 Non-IFRS Value 20000 15000 10000 5000 0 17
Slide 18: Medtech portfolio clusters
Medtech portfolio clusters Home Urology & Spine & Cardiology, Neurology Healthcare Women’s Health Orthopedics & Anesthesia IFRS Value: US$5,703 IFRS Value: US$15,018 IFRS Value: US$11,343 IFRS Value: US$9,786 Non-IFRS: US$10,156 Non-IFRS: US$27,925 Non-IFRS: US$14,551 Non-IFRS: US$15,820 AyzerSense
Slide 19: Agrifood portfolio clusters
Agrifood portfolio clusters Crop Digitization Future Food Protection & Robotics & Ingredients IFRS Value: US$7,209 IFRS Value: US$6,753 IFRS Value: US$12,233 Non-IFRS: US$9,026 Non-IFRS: US$12,515 Non-IFRS: US$17,166 EcoPhage | AgroScout | FruitSpec | AlgaHealth | Celleste | IBI-Ag | ProJini MetoMot
Slide 20: Book value vs. exit value
Book value vs. exit value US$ millions 60 50 40 30 4.4X is the increase in value 20 of our ten exits, compared to 10 their pre-exit book value. 0 Trendlines’ pre-exit book value Trendlines’ book value at exit 20
Slide 21: H1 2023: Key Financial Metrics
H1 2023: Key Financial Metrics 30 June 2023 31 December 2022 Portfolio value: US$101.0 million US$89.8 million Total Equity: US$104.1 million US$95.9 million NAV per share: US$0.11 (S$0.15) US$0.11 (S$0.15) Net profit/(loss) US$4.3 million profit vs (US$11.9) million loss in H1 2022 21
Slide 22: Balance sheet (Group)
Balance sheet (Group) Assets (US$’000) (US$’000) Current assets 30 June 2023 31 December 2022 Non-current assets 30 June 2023 31 December 2022 Cash and cash Investments in portfolio 4,574 4,565 101,013 89,777 equivalents companies Short-term bank Accounts and other 2,156 2,092 57 1,489 deposits rece
Slide 23: Balance sheet (Group)
Balance sheet (Group) Liabilities (US$’000) (US$’000) Current liabilities 30 June 2023 31 Dec 2022 Long-Term liabilities 30 June 2023 31 Dec 2022 Lease liability 352 419 Loans from the Israel 2,785 2,469 Innovation Authority Short-term loan 292 292 Deferred revenues 331 888 Trade and other 2,145 3,3
Slide 24: Consolidated condensed report of income (Group)
Consolidated condensed report of income (Group) Consolidated statements of profit or loss (US$’000) Income 30 June 2023 30 June 2022 Gain/(Loss) from change in fair value of investments in portfolio companies 9,192 (7,442) Income from services to portfolio companies 1,723 1,257 Income from contracte
Slide 25: Consolidated condensed report of income (Group)
Consolidated condensed report of income (Group) Consolidated statements of profit or loss (US$’000) Expenses 30 June 2023 30 June 2022 Operating, general and administrative expenses 4,430 5,020 Marketing expenses 134 167 R&D expenses, net 999 1,164 Financial expenses 1,471 2,287 Total expenses 7,034
Slide 26: H1 2023 achievements
H1 2023 achievements. “s: trendlines
Slide 27: Selected 2023 achievements
Selected 2023 achievements Selected raises Strategic collaborations Regulatory Clinical & field trials FDA clearance €5.5 million EIC funding FDA clearance S$1.4 million FDA clearance for US$2 million 2nd gen device 27
Slide 28: Investing to improve the human condition
Investing to improve the human condition SGX: 42T Steve Rhodes, Chair and CEO OTCQX: TRNLY steve@trendlines.com +972.72.260.7000 Todd Dollinger, Chair and CEO www.trendlines.com todd@trendlines.com Haim Brosh, CFO August 2023 haim@trendlines.com
Slide 29: Notes and Disclaimer
Notes and Disclaimer The additional information (Non-IFRS value) which, as stated, differs from the IFRS fair value at which we carry these investments on our balance sheet, were calculated on the basis of recent portfolio company transactions (last 12 months), as follows: 1. In cases where the last
The Trendlines Group — Investor Presentation (August 2023) on 6ix